Mark Iwicki is a seasoned executive and board leader in the biotechnology and pharmaceuticals industry. Currently serving as Chief Executive Officer at Inhibikase Therapeutics, Inc. since February 2025, Iwicki has held multiple board chair positions at Q32 Bio Inc., Third Harmonic Bio, Akero Therapeutics, and KALA BIO. Iwicki also holds directorships with Merus and Nimbus Therapeutics, demonstrating a strong commitment to advancing health solutions. Previous leadership roles include Board Chair at Aerovate Therapeutics and Director at Pulmatrix Inc. and Aimmune Therapeutics. Iwicki earned a Master of Business Administration with a focus on Marketing and Finance from Loyola University Maryland and a Bachelor of Science in Business Administration from Ball State University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices